Equities analysts expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post sales of $21.80 million for the current quarter, according to Zacks. Five analysts have issued estimates for Agios Pharmaceuticals’ earnings. The highest sales estimate is $24.60 million and the lowest is $19.50 million. Agios Pharmaceuticals posted sales of $8.76 million in the same quarter last year, which would indicate a positive year over year growth rate of 148.9%. The firm is expected to report its next earnings report on Friday, May 3rd.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $115.93 million for the current year, with estimates ranging from $100.00 million to $143.10 million. For the next fiscal year, analysts anticipate that the firm will post sales of $154.68 million, with estimates ranging from $114.00 million to $187.30 million. Zacks’ sales averages are an average based on a survey of analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.65) by $0.07. Agios Pharmaceuticals had a negative return on equity of 44.13% and a negative net margin of 366.61%. The firm had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $19.98 million. During the same period last year, the firm earned ($1.81) EPS. The company’s quarterly revenue was up 200.0% on a year-over-year basis.
AGIO stock opened at $58.68 on Wednesday. Agios Pharmaceuticals has a 12-month low of $41.63 and a 12-month high of $99.82. The stock has a market capitalization of $3.31 billion, a P/E ratio of -9.73 and a beta of 2.38.
In other Agios Pharmaceuticals news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $67.71, for a total value of $203,130.00. Following the transaction, the insider now directly owns 29,511 shares of the company’s stock, valued at approximately $1,998,189.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Bowden sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $64.16, for a total transaction of $641,600.00. The disclosure for this sale can be found here. Insiders sold a total of 42,000 shares of company stock worth $2,765,530 over the last three months. Corporate insiders own 3.02% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantamental Technologies LLC purchased a new position in Agios Pharmaceuticals in the 4th quarter worth approximately $28,000. Advisor Group Inc. lifted its stake in Agios Pharmaceuticals by 33.1% in the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 297 shares in the last quarter. ETF Managers Group LLC lifted its stake in Agios Pharmaceuticals by 15.7% in the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 216 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at approximately $257,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at approximately $262,000. 98.77% of the stock is currently owned by institutional investors and hedge funds.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.
Featured Article: Why do companies issue convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.